NeuExcell Therapeutics is a clinical-stage gene therapy company developing first-in-class treatments for neurodegenerative diseases. We are advancing three pioneering clinical trials in glioma, Alzheimer's disease, and stroke. Our proprietary ATN Astrocytes To Neurons™ platform converts supporting glial cells into functional neurons, repairing damaged brain tissue at the injury sites. This breakthrough approach has the potential to address a wide range of conditions, from stroke and Alzheimer's to glioma, Parkinson's, traumatic brain injury, spinal cord injury, ALS, and ocular diseases.
Our mission is to restore neural functions for millions of patients worldwide.
CORE TECHNOLOGY
NeuExcell's core technology achieves the therapeutic effect of neuroregeneration and repair through in situ ATN ASTROCYTES TO NEURONSTM platform technology.
NeuExcell's in situ neuroregeneration technology platform, which uses endogenous glial cells to regenerate neurons in vivo, is suitable for the treatment of many major neurological diseases, including stroke, Huntington's disease, ALS, Alzheimer's disease, Parkinson's disease, traumatic brain injury, spinal cord injury, epilepsy, Ophthalmic diseases, and glioma.
Founder | Chief Scientific Advisor
“ NeuExcell is pioneering a universal in vivo neuroregeneration technology, turning brain internal glial cells into functional new neurons in situ. Our world-leading Astrocyte-to-Neuron conversion platform is in clinical phase and has shown efficacy in patients. We believe this groundbreaking technology will transform neuroscience medicine by replenishing neurons to restore lost functions for millions of patients worldwide.”